Revance Therapeutics (NASDAQ:RVNC) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Revance Therapeutics (NASDAQ:RVNCGet Rating) from a sell rating to a hold rating in a research report report published on Monday morning.

Other equities analysts also recently issued reports about the company. Cowen lifted their price target on Revance Therapeutics from $55.00 to $65.00 in a research note on Thursday, September 8th. Guggenheim upped their price target on Revance Therapeutics to $35.00 in a report on Monday, August 15th. Cowen upped their price target on Revance Therapeutics from $55.00 to $65.00 in a report on Thursday, September 8th. Barclays upped their price target on Revance Therapeutics from $22.00 to $35.00 and gave the company an overweight rating in a report on Friday, September 9th. Finally, Needham & Company LLC lifted their price objective on shares of Revance Therapeutics from $25.00 to $35.00 and gave the stock a buy rating in a research report on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $39.75.

Revance Therapeutics Trading Up 2.6 %

NASDAQ:RVNC opened at $26.61 on Monday. The business’s 50-day moving average is $20.04 and its two-hundred day moving average is $17.32. The company has a debt-to-equity ratio of 14.80, a current ratio of 3.38 and a quick ratio of 3.20. Revance Therapeutics has a 12 month low of $11.27 and a 12 month high of $30.00. The firm has a market capitalization of $1.95 billion, a PE ratio of -6.91 and a beta of 0.92.

Revance Therapeutics (NASDAQ:RVNCGet Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.03. Revance Therapeutics had a negative return on equity of 497.77% and a negative net margin of 265.04%. The business had revenue of $28.37 million for the quarter, compared to analyst estimates of $27.64 million. Research analysts predict that Revance Therapeutics will post -3.69 earnings per share for the current fiscal year.

Insider Activity at Revance Therapeutics

In other Revance Therapeutics news, SVP Dwight Moxie sold 11,000 shares of the stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $27.07, for a total value of $297,770.00. Following the sale, the senior vice president now directly owns 31,694 shares in the company, valued at $857,956.58. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Revance Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisor Group Holdings Inc. boosted its holdings in shares of Revance Therapeutics by 60.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 1,071 shares during the period. Prospera Financial Services Inc acquired a new position in shares of Revance Therapeutics in the 1st quarter valued at approximately $122,000. Point72 Hong Kong Ltd bought a new stake in shares of Revance Therapeutics during the 2nd quarter valued at approximately $92,000. Carnegie Capital Asset Management LLC bought a new stake in shares of Revance Therapeutics during the 2nd quarter valued at approximately $290,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of Revance Therapeutics during the 4th quarter valued at approximately $175,000. 77.08% of the stock is currently owned by institutional investors and hedge funds.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Articles

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.